| Detected | Trial | Change |
|---|---|---|
| 2026-06-04 | NCT04430894 KRDI in Transplant-Eligible MM |
date change Completion pushed: 2026-03-30 -> 2026-12-30 |
| 2026-06-02 | NCT07601100 Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant… |
Primary endpoint(s) modified |
| 2026-06-02 | NCT07601100 Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant… |
Trial arms changed: 2 -> 6 |
| 2026-05-27 | NCT06203912 Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or… |
date change Primary completion moved earlier: 2026-08-31 -> 2026-05-19 |
| 2026-05-15 | NCT07479979 Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With… |
Recruitment opened |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-03 | NCT07624513 Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction… | Phase 3 | Not Yet Recruiting |
| 2026-05-22 | NCT07601100 Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant… | Phase 1/2 | Not Yet Recruiting |
| 2026-05-20 | NCT07600151 Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | Phase 1/2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06216158 | Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly… | Multiple Myeloma | Recruiting |
| NCT06182774 | Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older… | Multiple Myeloma | Recruiting |
| NCT03617731 | Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd)… | Multiple Myeloma | Active, Not Recruiting |
| NCT04751877 | Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone… | Multiple Myeloma | Active, Not Recruiting |
| NCT03319667 | A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib… | Plasma Cell Myeloma | Active, Not Recruiting |
| NCT07624513 | Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction… | Multiple Myeloma | Not Yet Recruiting |
| Phase 2 | |||
| NCT05922501 | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma | Relapsed Cancer | Recruiting |
| NCT06648889 | Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38… | T-ALL | Recruiting |
| NCT04240054 | Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in… | Multiple Myeloma | Recruiting |
| NCT05344833 | Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal… | Multiple Myeloma | Recruiting |
| NCT06356571 | A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and… | Plasma Cell Myeloma Refractory | Recruiting |
| NCT06832865 | ELISA in Relapsed/Refractory MM | Relapsed Refractory Multiple Myeloma (RRMM) | Recruiting |
| NCT05272826 | Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE… | Multiple Myeloma | Recruiting |
| NCT05145400 | Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | Multiple Myeloma | Recruiting |
| NCT05776979 | Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk… | Multiple Myeloma | Recruiting |
| NCT05704049 | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and… | Relapsed/Refractory Multiple Myeloma | Active, Not Recruiting |
| NCT04883242 | Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or… | Recurrent Multiple Myeloma | Active, Not Recruiting |
| NCT05690984 | Elimination of Minimal Residual Disease After Transplant | Multiple Myeloma | Active, Not Recruiting |
| NCT04835129 | Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory… | Multiple Myeloma | Active, Not Recruiting |
| NCT05873205 | Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias… | Blood Cancer | Active, Not Recruiting |
| NCT02960555 | Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple… | Smoldering Plasma Cell Myeloma | Active, Not Recruiting |
| NCT04653246 | Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM | Multiple Myeloma | Active, Not Recruiting |
| NCT03104842 | Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab… | Multiple Myeloma | Active, Not Recruiting |
| NCT04430894 | KRDI in Transplant-Eligible MM | Multiple Myeloma | Active, Not Recruiting |
| NCT05911321 | Isa-Pom-Dex in Elderly/Frail Subjects With RRMM | Multiple Myeloma | Active, Not Recruiting |